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ABSTRACT 
Artemisinin-based combination therapy is exerting novel selective pressure upon populations of Plasmodium 
falciparum across Africa. Levels of resistance to non-artemisinin partner drugs differ among parasite 
populations, and so the artemisinins are not uniformly protected from developing resistance, already present 
in South East Asia. Here, we consider strategies for prolonging the period of high level efficacy of combination 
therapy for two particular endemicities common in Africa. Under high intensity transmission, two alternating 
first-line combinations, ideally with antagonistic selective effects on the parasite genome, are advocated for 
paediatric malaria cases. This leaves second-line and other therapies for adult cases, and for intermittent 
preventive therapy. The drug portfolio would be selected to protect the “premier” combination regimen from 
selection for resistance, while maximising impact on severe disease and mortality in children. In endemic areas 
subject to low, seasonal transmission of Plasmodium falciparum, such a strategy may deliver little benefit, as 
children represent a minority of cases. Nevertheless, the deployment of other drug-based interventions in low 
transmission and highly seasonal areas, such as mass drug administration aimed to interrupt malaria 
transmission, or intermittent preventive therapy, does provide an opportunity to diversify drug pressure. We 
thus propose an integrated approach to drug deployment, which minimises direct selective pressure on 
parasite populations from any one drug component. This approach is suitable for qualitatively and 
quantitatively different burdens of malaria, and should be supported by a programme of routine surveillance 
for emerging resistance.  
 
INTRODUCTION  
The efficacy of antimalarial drugs used for the treatment of 
uncomplicated cases of falciparum malaria declined sharply in 
the last decade of the twentieth century in sub-Saharan Africa; 
this had already been observed in malaria endemic areas in 
Asia in the 1980s. The current decade is seeing the continued 
widespread deployment of artemisinin-based combination 
therapy (ACT) as first-line therapies to replace those drugs that 
are judged to have reached an unacceptable level of treatment 
failure. The number of ACT regimens with proven efficacy and 
safety is small, and currently only artemether-lumefantrine 
(AL), sulphadoxine-pyrimethamine plus artesunate (SPAS) and 
amodiaquine plus artesunate (AQAS) are widely used in Africa. 
Other combinations in an advanced stage of development and 
which may soon be routinely deployed in some countries 
include dihydroartemisinin / piperaquine (DP) and 
pyronaridine/artesunate (PYAS). Whereas some of these 
partner drugs have not been used previously in Africa, both 
amodiaquine and the anti-folates have been widely used, and 
lumefantrine is related to other previously used drugs such as 
halofantrine. Thus some ACT regimens may be deployed in 
areas where the parasite population has had some previous 
exposure to one or more of the partner drugs (or chemically-
related compounds), and may be expected to have some 
Sutherland CJ, Babiker H, Mackinnon MJ, Ranford-Cartwright L, El Sayed BB. 2011.  AUTHOR MANUSCRIPT 
Rational deployment of antimalarial drugs in Africa: should first-line combination drugs be reserved for paediatric malaria cases?  
Parasitology. 138: 1459-1468. 
 2 
underlying tolerance of, or limited resistance to, the 
combination. Careful consideration is required to ensure that 
malaria treatment policy, in striving to deliver the best clinical 
outcome for the greatest majority of treated individuals, does 
not generate a level of selection that causes rapid spread of 
resistance and erosion of therapeutic efficacy.  
 It is important to clearly define our intended 
meaning for the terms efficacy and strength of selection for 
the argument to follow, as these are not congruent. Efficacy of 
a single agent or combination regimen is intended to mean the 
operationally measurable outcome of in vivo efficacy studies: 
the absence of clinical or parasitological (microscopically 
detected) recurrence during 28 days of follow-up in a cohort of 
treated patients taking observed treatment doses. Strength of 
selection exerted by a regimen is not usually directly 
measurable, but here will signify the relative transmission 
advantage of a parasite genotype harbouring a mutation or 
mutations conferring reduced sensitivity (or resistance) to the 
regimen of interest, compared to genotypes lacking that 
mutation or mutations. In some studies this can be estimated 
from single time-point measures (e.g. day 7 or day 14 post-
treatment) of genotype prevalence in infected Anopheles 
mosquitoes fed on blood from treated, infected individuals 
(Bousema et al. 2006; Hallett et al. 2006).  This approach does 
not fully capture the transmissibility of different genotypes 
over extended time periods following treatment. The 
magnitude of selection could be better envisaged as the 
difference between the proportion of all post-treatment 
transmission events with non-wild-type genotypes (at loci 
implicated in resistance to the regimen used) and the 
proportion of such genotypes in the pre-treatment population. 
As Hallett et al. (2006) and Mendez et al. (2007) have shown, 
selection for transmission of advantageous genotypes can 
occur even when drug efficacy appears good.  
 Recent studies in Cambodia demonstrate a 
measurable reduction in the sensitivity of P. falciparum to 
artemisinin monotherapy in some areas, although treatment 
responses for ACTs remain satisfactory (Noedl et al. 2008; 
Dondorp et al. 2009). These observations suggest both an 
urgent need to develop strategies to protect ACT worldwide 
from the effects of possible spread of such parasites, and the 
necessity of implementing suitable surveillance of ACT efficacy 
throughout malaria endemic regions. In sub-Saharan Africa, 
where artemisinin monotherapy trials have not been 
performed, and where efficacy of ACT remains good or very 
good, protection of the efficacy of drug combinations now in 
use must be the first priority, and thus the opportunity for 
artemisinin-resistant P. falciparum to enter, or arise in, Africa 
must be minimised. The importance of this task is further 
emphasised by the recent demonstration that use of 
parenteral artesunate in place of quinine is able to reduce the 
death rate among hospitalised African children with severe 
malaria (Dondorp et al. 2010). Among the possible strategies 
to protect current regimens from the development of parasite 
resistance are lengthening of the duration of ACT treatment 
and/or increasing the total dosage given, or using additional 
partner drugs with existing dual-component combinations, 
essentially to maintain effective parasiticidal blood levels of as 
many component drugs as possible for as long as possible. 
Early in its development, a newly arising form of resistant 
parasites is likely to remain sensitive to high blood 
concentrations of the drug, but enjoy an advantage once drug 
levels fall, at concentrations still lethal to the wild-type. In fact, 
even fully developed supposedly CQ-resistant genotypes in 
Africa have been shown to be sensitive to unorthodox CQ 
regimens that distribute higher total drug dosage using more 
frequent individual doses (Ursing et al. 2007, 2011). Regarding 
the former, extension of AL regimens from 4 days to 6 days in 
The Gambia reduced the rate of recurrent parasitaemia, and 
was associated with a demonstrable benefit in reduced 
gametocyte carriage (Sutherland et al. 2005). In Guinea-Bissau, 
higher doses of CQ given for longer (5 – 7 days) have been 
delivered safely by the use of split-doses. This regimen was 
associated with continued efficacy against P. falciparum 
carrying parasites with known CQ-resistant genotypes at the 
pfcrt and pfmdr1 loci, and a reduced selective advantage of 
these mutant genotypes. This appears to have contributed to a 
significant extension of the effective life of CQ in that country 
(Ursing et al. 2007, 2011). Similarly, increasing and extending 
mefloquine (MQ) dosage as part of the MQAS combination 
stopped the decline in efficacy of the combination that had 
been evident when lower doses were used in Thailand (Carrara 
et al. 2009). This may not necessarily mean that the selective 
advantage of resistant genotypes (in this case copy number 
amplification of the pfmdr1 locus) has been neutralised; it is 
important to emphasise that even where drug efficacy is 
acceptable, selection for advantageous genotypes will still 
occur (Hallet et al. 2006). As for implementing artemisinin-
based regimens with two or more partner drugs, this option 
must at least be considered as a plausible strategy, by analogy 
with chemotherapeutics against other infections such as 
tuberculosis and HIV. However we will not focus on either of 
these strategies in the current paper. 
 An alternative way of protecting ACT is to devise an 
innovative approach to antimalarial drug deployment across 
endemic country health systems, with the intention of 
generating diverse, “polyvalent” drug pressure. This would be 
designed to prevent (or slow) the emergence of parasite 
genotypes with a survival advantage under the major 
treatment regime. As the pattern of resistance to partner 
drugs may vary across different endemic settings, so will the 
level of direct selection pressure on parasite populations that 
is exerted by the artemisinin components themselves. Such 
selection pressure will be strongest where the efficacy of the 
partner drugs offer less protection for the artemisinin; it 
follows that protection of partner drug efficacy is an important 
component of any strategy to sustain the useful life of ACT. 
Therefore, interventions can be planned in an integrated way 
within countries, and even within regional groupings of 
different nations, so as to maximise partner drug efficacy, and 
so minimise additional selection acting directly on the 
artemisinin component of ACT. Such rational, integrated 
planning might use not only the principal strategy of partner 
drug diversification, but also where possible the deployment of 
non-artemisinin regimens for intermittent preventive therapy 
and treatment of clinical malaria cases in semi-immune 
individuals.  
 The primary objective of such integration is to reduce 
the selection for parasites resistant to the first-line 
combination(s) in order to prolong the useful life of the 
artemisinin components. In this paper we propose that, in high 
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transmission settings, rational deployment requires 
preservation of the front-line ACT treatment for children, who 
are at the most risk of severe, life-threatening malaria. Adult 
malaria cases can then be treated with either an alternative 
ACT or a non-ACT combination, and drug-based preventive 
interventions such as IPTp and IPTi could be restricted to 
alternative non-artemisinin combination regimens. Policies in 
each country would be coordinated with, and deliberately 
complementary to, the policies of other countries in the 
region, wherever possible. Secondly, in low transmission 
settings, with Eastern Sudan considered as a specific example, 
we argue that paediatric targeting would be of little benefit. 
Nevertheless, the interruption of transmission by an extended 
dry season each year offers particular opportunities for 
preventative use of antimalarial drugs. Finally, we explore the 
options for surveillance and monitoring suitable for African 
settings, and recommend a newly developed approach to 
detect early signs of emerging resistance to ACT-based 
antimalarial therapies in the field under different transmission 
settings.  
 
Integrated Use of Antimalarial Drugs in Malaria Control  
A National Malaria Control Programme manages a range of 
activities aimed at minimising malaria-related morbidity and 
mortality, and at reducing malaria transmission. Here, we will 
consider only those activities that employ antimalarial drugs. 
Undoubtedly the interaction between vector control or 
personal protection (e.g. impregnated bednets) and 
antimalarial-based strategies will have an important bearing on 
the possible emergence of ACT-resistant parasites, but is 
beyond the scope of the current discussion. These activities 
can be listed thus: 
1. Chemotherapy for confirmed clinical malaria cases in 
children under 10 years 
2. Chemotherapy for confirmed clinical malaria cases in 
people over 10 years 
3. IPTi  for protection of infants, linked to standard EPI 
visits  
4. IPTc  for protection of children aged 2 – 5 years (high 
transmission seasonal settings only)  
 or   IPTc  for school-aged children  
5. IPTp for pregnant women 
 
Each of these 5 uses of drugs may put infecting malaria 
parasites under variable levels of selection pressure. This is 
due to : 
- different amounts of transmission from one recipient 
group to the others,  
- acquired immunity being more common in older 
groups and  
- IPT being administered to people with lower overall 
parasite burdens than those presenting with clinical 
malaria.  
Where drug is the principal effector of parasite clearance, as in 
young non-immune children, we would expect intense 
directional selection for resistant parasites following 
treatment. However, in semi-immune individuals parasite 
clearance is a collaboration between direct drug effect and 
immunity (Diallo et al. 2007) and thus the intensity of selection 
on resistance-associated loci will be reduced. The magnitude of 
this reduction will depend both on the prevalence of effective 
immunity in that treated group, level of drug coverage and the 
degree of advantage afforded by the parasite resistance 
mechanism. Further, survival of a (small) proportion of the 
parasite population is more likely with higher parasite 
densities, as evidenced by the relationship between parasite 
clearance time and starting parasitaemia in vivo (Dondorp et 
al. 2009; Beshir et al. 2010a). Therefore, it seems likely that 
selection intensity will be greater with drug use against clinical 
malaria episodes, in non-immune adults and children, than 
with drug use for prophylaxis, or for suppression of pre-
existing, low density asymptomatic infection, as in semi-
immune individuals.  Although more work is required to 
determine whether this is the case, Dunyo et al. (2006), in a 
large cross-sectional survey, found that asymptomatic 
infections not only had lower asexual parasite densities, but 
lower gametocyte prevalence. Further, when these individuals 
were treated and followed for three months, the area under 
the gametocyte carriage curve was significantly smaller than 
among individuals initially with clinical (high parasite density) 
malaria treated with the same regimen, suggesting reduced 
asexual parasite survival among the former. (Nevertheless, 
asymptomatic individuals may represent a large proportion of 
infections in high transmission settings and so may constitute a 
significant source of drug-exposed parasites in some 
circumstances.) With these arguments in mind, we have 
therefore presented activities 1 to 5 in the order of expected 
decreasing intensity of drug pressure and thus decreasing 
potential for selection and transmission of drug resistance 
genotypes.  
  
Some antimalarial drugs exert opposite directional selection 
on parasite genotypes  
After taking into account the hierarchy of selection intensity 
discussed in the preceding paragraph, the framework we wish 
to propose is then under-pinned by already existing (and some 
yet to be gathered) knowledge of degrees of drug sensitivity 
afforded by different parasite genotypes at key loci known to 
influence treatment responses in vivo and in vitro. Table 1 lists 
existing evidence from African settings on directional selection 
exerted by antimalarial drugs of interest on two of the loci 
implicated in parasite response to treatment, pfmdr1 and 
pfcrt. Selective effects of piperaquine and pyronaridine in vivo 
remain unclear, although a recent report using a previously 
untested methodology found evidence of an association 
between carriage of pfmdr1 encoding a tyrosine at codon 1246 
and treatment failure with DP in malaria patients in Papua 
New Guinea (Wong et al. 2011). Thus additional knowledge is 
needed. A particularly interesting feature is the directionally 
opposed selection exerted by amodiaquine and artemisinin / 
lumefantrine on both pfmdr1 and pfcrt (Humphreys et al. 
2007; Sisowath et al. 2009). Thus integrated use of 
amodiaquine-containing combinations and AL against the 
same parasite population is predicted to provide a reduction of 
selective effect for both regimens. In east Africa, amodiaquine 
has reduced efficacy due to the relatively high prevalence of 
the pfmdr1 YYY haplotype, and the pfcrt IETSE haplotype 
(Table 1; Holmgren et al. 2007; Humphreys et al. 2007), and 
thus this strategy is very likely to be compromised. However in 
west Africa, amodiaquine – based regimens retain good 
efficacy (Ursing et al. 2007; Sirima et al. 2009) and a 
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“longitudinal paired combinations” strategy utilising AL and 
ASAQ, as described below, could be deployed there.  
 It has been argued that the recently reported 
presence in Angola of P. falciparum harbouring the SVMNT 
haplotype of pfcrt at codons 72-76 seriously threatens the 
usefulness of AQ-containing combinations across the continent 
(Sa and Twu, 2010). Although this is not yet a proven threat, as 
there are insufficient in vivo data to evaluate the efficacy and 
selective effect of AQ-containing combinations against 
parasites with the SVMNT haplotype, ASAQ performed less 
well than other ACT regimens in a recent study in Burma 
(Smtihuis et al. 2010), where SVMNT parasite are expected to 
occur. It is now important to investigate whether this 
haplotype enjoys a selective advantage under ASAQ in Asia and 
Africa. The poor penetration of this genotype into Africa 
suggests it does not enjoy a meaningful fitness advantage in 
the absence of high levels of AQ selection, and in the presence 
of acquired immunity to malaria in many individuals. In 
particular, parasites with this pfcrt genotype are not highly 
chloroquine resistant, and are reliant on the presence of 
particular haplotypes of pfmdr1 to survive CQ or AQ treatment 
(Sa et al. 2009). Together with the much higher levels of intra-
host competition among parasite genotypes in African human 
populations, due to higher multiplicity of infection and 
enhanced immunity, this may explain the failure of SVMNT 
genotype to flourish in Africa as they have done in South 
America, The Philippines, India, Pakistan and Afghanistan (Ord 
et al. 2007; Beshir et al. 2010b).  More in vivo efficacy data are 
needed to resolve this question.  
 
Targetting paediatric malaria cases with longitudinally paired 
antimalarial combinations  
As discussed above, treatment of young children with clinical 
malaria is the most likely activity to exert intense selection on 
P. falciparum genotypes at the population level in high 
transmission settings. Therefore we propose targeted 
paediatric therapy with a novel strategy consisting of two, 
alternating, highly effective combination antimalarial regimens 
(Table 2). These should be chosen such that, where possible, 
the non-artemisinin partners exert opposite directional 
selection on key resistance-associated loci. This strategy could, 
for example, deploy ASAQ as first-line treatment for children 
under 10 years presenting with confirmed P. falciparum 
malaria, but at the next episode experienced by that child, AL 
would be provided. For the third, fifth and seventh episodes of 
malaria ASAQ would again be administered, with AL given at 
the fourth and sixth. Thus in any one individual, each 
subsequent malaria episode is treated with a drug combination 
that should display good efficacy against any parasites that 
may have persisted, and been selected for a particular allele of 
pfmdr1, from the previous malaria episode. This alternative 
first-line regimen would also be used as “second-line” 
treatment administered due to clinical symptoms persisting or 
recurring within 28 days of treatment of a clinical malaria 
episode. Although efficacy is good in most of sub-Saharan 
Africa (Sirima et al. 2009), ASAQ performs less well in some 
countries (Zwang et al. 2009; Smithuis et al. 2010), and 
mefloquine-artesunate (MQAS) may be the best choice as an 
alternative. Caveats to be considered are the relatively high 
cost of mefloquine, and the need for pharmacovigilance in 
situations where subsequent regimens overlap closely; it is 
known that the administration of halofantrine in patients with 
persisting blood levels of mefloquine increases the risk of 
cardiotoxicity (Bouchaud et al. 2009). Although this alternating 
approach requires good record-keeping to maintain the 
pattern of drug alternation, these records will also provide 
useful information on the periodicity of malaria episodes 
requiring treatment in children, and thus could be used as part 
of ongoing routine surveillance of treatment efficacy. Thus 
implementation of such a strategy could be beneficially 
coupled to capacity development in the periphery of African 
health systems. This strategy specifically deploys, at the 
individual level, pairs of combination regimens for which some 
evidence of antagonistic selection on the parasite genome 
exists (based on previously identified markers of resistance 
such as pfmdr1). In such cases, it is expected to perform better 
than strategies using concurrent or time-revolving mixtures of 
drugs at the population level. When such antagonism does not 
exist, care must be taken when treating persistent infections 
with a different drug since this may enhance the development 
of multi-drug resistance. Further, if drug cross-resistance 
occurs as in the case of CQ and AQ, sequential use is very likely 
to lead to poor therapeutic outcomes for the second malaria 
episode. Unfortunately, in most clinical settings there are few 
choices available for second-line therapy. 
 
Treating adults with malaria  
Do African adults with uncomplicated symptomatic malaria 
need to be treated with ACT? In high transmission areas, 
where the prevalence of acquired immunity is significant, we 
would argue that they do not. Treating adults with an effective 
combination of two non-artemisinin partners would be 
cheaper and, due to the lower proportion of infected adults 
being treated, and the relatively important contribution of 
immunity to the treatment outcome, would reduce the 
selective pressure on P. falciparum populations towards the 
development of artemisinin resistance. One such combination 
likely to be very effective in West Africa is piperaquine plus SP, 
a regimen recently successfully trialled for use for IPTc in 
children from both Senegal (Cisse et al. 2009) and The Gambia 
(Bojang et al. 2010). Further, these three relatively long half-
life drugs would offer each other mutual protection towards 
the right-hand end of the pharmacodynamic curve. This may 
only be prudent where the piperaquine-containing ACT DP was 
not in use as a first-line regimen for children.  
 
Restricting therapeutics to malaria cases confirmed by 
diagnosis 
The well documented pan-African spread of parasites resistant 
to CQ, SP or both was almost certainly assisted by selective 
pressure due to chemotherapy unnecessarily administered to 
febrile patients presumed to be suffering from clinical malaria. 
Uncertain diagnosis and over estimation of malaria in most 
African primary health-care settings can lead to frequent 
prescription of anti-malarials to both children and adults who 
do not have malaria (Reyburn et al. 2004), and substantially 
higher drug pressure than necessary. The selective pressure 
exerted by unwarranted therapy is likely to be substantially 
higher as parasites acquired subsequent to this treatment may 
emerge into the bloodstream and encounter falling, sub-
therapeutic drug levels , particularly for component drugs with 
long half-lives. This can only be prevented by the appropriate 
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use of diagnostics prior to treatment of every suspected case 
of clinical malaria. Curiously, there are theoretical reasons to 
argue that mis-use of SP in particular may have improved the 
rate of development of anti-parasite immunity in some 
settings (Sutherland et al. 2007; Gosling et al. 2008). However, 
the possible existence of such an unexpected benefit of 
improper drug use does not mean that there is no price to be 
paid in terms of avoidable drug selection pressure on the P. 
falciparum genome.  
  
Where children are not the main group at risk – the example 
of eastern Sudan  
As presented above, two considerations are important here: 
maximising drug efficacy at a given frequency of resistance, 
and reducing the selective advantage of resistant genotypes. 
The impact of P. falciparum drug resistance on the highly 
seasonal malaria transmission around the town of Gedarif, in 
eastern Sudan has been well studied for two decades (Bayoumi 
et al. 1989, 1993; Abdel-Muhsin et al. 2004; Adam et al, 2004; 
Babiker et al. 2005; Nassir et al. 2005; Al-Saai et al. 2009; 
Gadalla  et al. 2010). Symptomatic malaria cases occur during a 
matter of weeks each year after brief seasonal rains, and may 
occur in all ages; with the majority of cases in older children 
and adults. Although asymptomatic chronic parasite carriage 
continues in a subset of people throughout the dry season, 
acquired immunity which protects against disease is not a 
prominent feature of populations in this setting. Thus, in 
contrast to higher transmission seasonal settings such as 
Burkina Faso (Diallo et al. 2007), a close correlation between 
carriage of parasites with drug resistant pfcrt or pfdhfr / pfdhps 
genotypes and treatment failure was observed for CQ and SP 
respectively during the 1990s and 2000s (Bayoumi et al. 1989; 
Babiker et al., 2001; Abdel-Muhsin et al., 2004; Al-Saai et al. 
2009). In other words, the impact of drug resistance on 
treatment outcomes here is not softened by the helping hand 
of previously acquired immunity. An additional intervention 
option, of particular relevance in this setting due to the 
occurrence of strict seasonality, is mass drug administration 
(MDA) to reduce or eliminate the dry season parasite reservoir 
among asymptomatic carriers before the new malaria season 
begins (von Seidlein et al. 2003; El Sayed et al. 2007). Due to 
the high coverage of drug used, this strategy may be 
particularly vulnerable to rapid selection of resistant parasite 
genotypes, and must not overlap with the front line 
therapeutic regimens for clinical cases.  
 
In such a setting then, it is particularly beneficial for 
chemotherapeutic interventions against P. falciparum to be 
designed to minimise the impact of selection for resistance. 
With this principle in mind, we suggest the following 
antimalarial drug deployment matrix for therapy in an 
intervention area such as the Gedarif region of Eastern Sudan: 
 
First-line therapy  AL 
(uncomplicated, parasitologically-confirmed malaria, all ages)  
 
Second-line therapy  AQ/AS 
(for relapses, treatment failures, adverse reactions to AL) 
 
Parenteral therapy for severe malaria  AS i.v. or oral (first-line)  
 QN i.v. or oral (second-line)  
 
Preventative therapy  DP + SP  (MDA)  
 
To maximise the useful therapeutic life of the first-line therapy, we have avoided SP/AS, a credible candidate which is currently in use in 
Sudan, because of evidence that SP-resistance is already present in this area (Al-Saai et al. 2009), whereas AL efficacy is good (Elamin et 
al, 2010). Thus in a small proportion of treated cases, SP/AS would not be providing the full benefit of combination therapy. This could 
dangerously expose AS to new tolerant or resistant parasites should they arise in the population or be imported from elsewhere. 
 
The second-line therapy is chosen to minimise the survival of any parasites persisting after treatment with AL. Recent studies have 
described the selective survival of parasites harbouring particular pfmdr1 mutations after AL treatment (Sisowath et al. 2007; 
Dokmalijar et al. 2006). However, Humphreys et al. (2007) demonstrated that AQ selects against these mutations, coding for the amino 
acids Gly (N), Phe (F) and Asp (D) at codons 86, 184 and 1246 of pfmdr1 (Table 1). Thus the use of AQ/AS may complement any previous 
AL treatment that did not clear parasitaemia, or at least failed to prevent a new infection with parasites carrying the NFD pfmdr1 
genotype.  
 
In-patient treatment for severe malaria in Africa is still usually provided by parenteral QN, although a recent multi-centre randomised 
trial found that intra-venous artesunate gives a small but significant reduction in mortality, from 10.9% to 8.5%, among severe malaria 
cases in hospitalised African children (Dondorp et al. 2010). Therefore we consider i.v. AS a preferable in-patient treatment. The 
numbers of severe, hospitalised malaria cases is a small proportion of total cases, and so the contribution of third-line treatment to 
Sutherland CJ, Babiker H, Mackinnon MJ, Ranford-Cartwright L, El Sayed BB. 2011.  AUTHOR MANUSCRIPT 
Rational deployment of antimalarial drugs in Africa: should first-line combination drugs be reserved for paediatric malaria cases?  
Parasitology. 138: 1459-1468. 
 6 
overall drug pressure on the parasite population is negligible. A possible exception to this is in epidemic outbreaks, which may occur in 
areas of seasonal transmission following years of no/low rains and pause in annual transmission (Bayoumi et al., 1989).  
 
Finally, preventive therapies in low intensity, highly seasonal settings such as Gedarif are probably restricted to MDA, as IPT for 
pregnant women or infants is not indicated where infection risk is so low. Although an argument can be made for the inclusion of 
primaquine in the MDA regimen, the risk of haemolysis requires screening for G6PD genotypes at risk, and so renders implementation 
difficult (Shekalage et al. 2010). Therefore we suggest DP (with reasonably good activity against developing gametocytes) plus SP to give 
a long pharmacodynamic tail comprising all three compounds. As SP resistant parasites are present in the study area, the impact on 
post-MDA parasite carriage needs to be closely monitored. A logistic difficulty with the DP plus SP regimen is the need to give multiple 
doses; compliance may fall if doses two and three of DP are not delivered, or at least observed, by health workers.    
 
A crucial role for surveillance and monitoring  
The rational deployment recommendations present above revolve around a single key imperative: to minimise the impact of resistant P. 
falciparum on the efficacy of artemisinin-containing combination regimens used to treat children with uncomplicated malaria only (high 
transmission areas) or uncomplicated malaria cases of all ages (low / seasonal transmission areas). Thus monitoring of antimalarial 
efficacy in children under 5 years or in cases of all ages, respectively, should be undertaken in these settings. When drug efficacy is high, 
passive monitoring, which normally entails recording cases of treatment failure that return to the health system requiring re-treatment, 
will provide little data of use. In fact only when substantial loss of efficacy has occurred will such an approach begin to indicate a 
measurable reduction in effectiveness of the malaria treatment programme. We , therefore, propose a simple approach to health-
system based active monitoring that could be promoted throughout Africa. This is based on the collection of a pair of finger-prick filter-
paper blood-spots at day 0 and day 2 (or day 3) of treatment i.e. immediately prior to treatment (normally a small portion of the 
diagnostic blood sample) and then 48 (or 72) hours later once treatment has finished. These blood-spots need only a few microlitres of 
blood and a simple dab of a pricked finger is sufficient. The paired day 0 and day 2 filter-papers are in-expensive, easily collected and 
can be stored desiccated at room temperature (but do require an additional contact with the patient). New methodologies now permit 
such paired samples to be used for quantitative analysis of parasite reduction rate by qPCR (Beshir et al. 2010a); this molecular test 
could easily be set up on a reference or regional lab basis and performed on a proportion of cases (perhaps 10-20%) for continuous 
monitoring of efficacy. Ideally, blood films would also be made on the additional visit and stored, but these would not normally need to 
be examined on the day of collection if the patient reports being well. For a small increase in capacity in the periphery, important 
monitoring information could thus be gathered in every health centre in Africa that dispenses antimalarial drugs. Together with the 
record-keeping required to operate the drug alternation system, this would greatly add to the surveillance capability of national malaria 
control programmes.  
 
CONCLUDING REMARKS  
Our approach assumes that parasites infecting hosts in the different compartments in the population targeted by the various uses of 
malaria drugs (children, symptomatic adults, infant and school-age recipients of IPT, pregnant women) are able to frequently transmit 
parasites to mosquitoes that will subsequently infect individuals in other compartments. In this way, parasites in a host from one 
compartment may be transmitted to a host in another compartment where the type of drug used differs, and their survival advantage 
may therefore be compromised, or even reversed in the case of antagonistic mechanisms of resistance. Thus the parasite population 
may be forced into a pattern of diversifying selection at key drug resistance loci, analogous to the selection exerted on parasite antigens 
by acquired immunity in people: the diversity of host immune responses leads to a balanced but dynamic diversity of alleles among 
genes encoding parasite proteins recognised by those responses that are protective (Polley et al. 2003; Weedall et al. 2007). Recent 
sequencing studies of pfcrt and pfmdr1 from African settings where monomorphic CQ drug pressure has been replaced by a diversity of 
drugs suggest that these two resistance-associated loci are now under diversifying selection (Sutherland & Polley, 2011; Gadalla et al. 
unpublished observations). Thus new mutations, currently at low frequency, may emerge and escalate in frequency. The response of 
parasites harbouring these newly recognised forms of pfcrt and pfmdr1 to the combination therapies currently being deployed across 
the African continent may be a crucial determinant of the long-term effectiveness of these regimens. The measures we have discussed 
do not require a substantial increase in programme costs, but may help sustain effectiveness for some extra years; we cannot dare to 
hope that current ACTs will retain good efficacy a decade or more hence. Thus an arsenal of new antimalarial drugs is desperately 
needed to replace the artemisinins and their current partners in the 2020’s.   
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DRUG 
Locus pfmdr1 pfcrt 
Other 
loci 
Codon 86 184 1246 74 75 76 220 271 
Wild-type N Y D M N K A Q 
chloroquine  Y F - I E T S E  
amodiaquine  Y Y Y I E T S E  
lumefantrine
a 
 N F D M N K A Q  
artemisinins
a
  N F D M N K A Q  
pyronaridine  - - - - - - - -  
piperaquine
b
  - - Y - - T - -  
mefloquine
c
  N Y D - - - - -  
sulfadoxine  none none none none none none none none pfdhps 
pyrimethamine  none none none none none none none none pfdhfr 
 
TABLE 1.  Known selective effects of antimalarial drugs on resistance loci of P. falciparum of African origin
d
.  
 
Dash ( - ) indicates lack of relevant data.  
a
The combination AL selects for these genotypes; available in vivo and in vitro data suggest both drug components may both contribute 
to this effect. 
b
A single in vitro study published to date suggests piperaquine may select for pfcrt 76T (Muangnoicharoen et al. 2009), but this has not 
been shown in vivo. A single study provides some evidence for selection for the 1246Y allele of pfmdr1 (Wong et al. 2011).  
c
There are no recorded cases of  mefloquine treatment failure in Africa in parasites which exhibited increased pfmdr1 copy number, as 
has been frequently described from Asia.  
d
Data summarized from the following studies: Humphreys et al. 2007; Sisowath et al. 2007, 2009; Dokmajilar et al. 2006; Duraisingh et 
al. 1997, 2000; Muangnoicharoen et al. 2009; Wong et al. 2011.   
 
 
 
 
INDICATION CHILDREN < 10 years ADOLESCENTS, ADULTS 
Uncomplicated falciparum 
malaria 
Alternating 
for 
subsequent 
episodes 
 
AQ/AS 
SP-PQ 
AL 
Treatment failure of above 
1. Alternate first-line drug 
2. DHA-PQ 
AL 
Severe hospitalized malaria
 1. Parenteral artesunate 
2. Parenteral quinine 
 
TABLE 2.  Hypothetical treatment matrix for reduction of drug resistance selection pressure in high transmission 
settings in West Africa (where AQ and SP currently retain good efficacy).   
 
  
